James P. Allison Institute at MD Anderson seeks to refocus immunotherapy research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

James Allison has reshaped cancer drug development, making checkpoint inhibitors a staple of therapy in many key indications—and dramatically improving survival outcomes in previously recalcitrant diseases.

Allison shared the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer (The Cancer Letter, Oct. 5, 2018). 

This innovation was so important that it has taken on a life of its own, spawning hundreds of trials, often of “me-too” compounds advanced by drug manufacturers vying to get duplicative versions of checkpoint inhibitors in efforts to gain a foothold in the immunotherapy market.

Now, Allison and colleagues at MD Anderson Cancer Center are trying to focus the scientific agenda, tackling the fundamental questions—starting with why do some patients benefit while others do not—and conducting studies that would result in expansion of knowledge about this class of drugs.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Matthew Bin Han Ong
Senior Editor
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Matthew Bin Han Ong
Senior Editor
Paul Goldberg
Editor & Publisher

Login